KEY SUPPORTERS

We are extremely grateful to the following organisations for their support:

AMGEN
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

CONSILIENT
At Consilient Health we are passionate about developing and supplying prescription medicines that provide benefits to Patients and Prescribers and the NHS. This is achieved through building strong partnerships with our manufacturing, distribution and pharmacy partners.
We offer one of the widest ranges of oral contraceptives in the UK, offering high quality products and significant savings for the NHS, complemented by comprehensive support programmes for both medical professionals and patients.
We launched our first Bone Health product in 2014 having identified an unmet need for prescribers and patients to have access to licenced medicines within the vitamin D therapeutic area.

ELI LILLY
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago, by a man committed to creating high-quality medicines that meet real needs and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at: www.lilly.co.uk

INTERNIS
Founded in 2010, Internis is a UK specialty pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency.

KYOWA KIRIN
Kyowa Kirin International PLC is a specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. Headquartered in Galashiels, Scotland, it is a subsidiary of Kyowa Hakko Kirin Co., Ltd., the Japan-based global specialty pharmaceutical company. Sales and marketing of its portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries. Website: www.kyowa-kirin.com.

MEREo
Mereo is a UK-based specialty biopharma company established to acquire and develop innovative products that may not have otherwise been developed within large pharma or big biotech. These companies have become under increasing pressure to streamline R&D therefore creating opportunities for Mereo.
Mereo’s aim is to become a leading biopharma company focussed on speciality and rare diseases with significant unmet needs.
Mereo’s initial portfolio is in respiratory, endocrinology and metabolic bone disease. Each of which has proof of efficacy data and address large unmet needs in either speciality or rare disease.
The company has advanced the respiratory and endocrinology products into Phase 2 and Phase 2b with data expected towards the end of the year and BPS 804 for Osteogenesis Imperfecta is about to start its Phase 2b study in adults. There is also an active search for new products.

UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,700 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
We are extremely grateful to the following organisations for their support:

**ALEXION**
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

**AMGEN**
See under Key supporters.

**BRUKER**
Offering the largest range of Preclinical Imaging systems, with an unmatched 9 in-vivo modalities, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging.
Benefiting from more than 5 decades of passionate innovation, Bruker customers enjoy a vast portfolio of possibility; from a single source they have endless opportunities for combining multiple modalities for seamless workflow and higher productivity. Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

**CONSLIENT**
See under Key supporters.

**ELI LILLY**
See under Key Supporters.

**INTERNIS**
See under Key Supporters.

**NATIONAL OSTEOPOROSIS SOCIETY**
At the National Osteoporosis Society, we understand that fractures can have shocking effects on day-to-day life. We are committed to helping people with osteoporosis live the lives they want to lead and we work every day to prevent future fractures. As the only UK-wide charity dedicated to ending the pain and suffering caused by osteoporosis we are here for anyone affected by the condition, providing help and support for people with osteoporosis now.

**VERTEC SCIENTIFIC**
Vertec are a leading UK distributor of diagnostic imaging and radiotherapy systems. They have sold and supported Hologic DXA in the UK since 1986 and have made it into the market leader in the UK.
Hologic invented DXA and have continued to develop it into a multi-faceted imaging tool providing the widest range of accessible applications, culminating in the new Horizon system. The range is very wide: Body Mass Index, Visceral Adipose Tissue studies, android/gynoid ratio, cardiac calcification scoring, Body Composition Analysis, single energy femur scan for evaluation of a typical femur fracture assessment and high definition mode for vertebral fracture assessment.
The concept that drives the Horizon is that it must be future proof with capabilities to meet evolving applications. Horizon is backed up by Vertec's customer focus which includes skilled applications specialists and service engineers to make sure you get the best from what we supply.
The Bone Research Society is extremely grateful to the following organisations who have supported the meeting: